With a worldwide prevalence of about 1 in 3500-5000 individuals, Retinitis Pigmentosa (RP) is the most common form of hereditary retinal degeneration. It is an extremely heterogeneous group of genetically determined retinal diseases leading to progressive loss of vision due to impairment of rod and cone photoreceptors. RP can be inherited as an autosomal-recessive, autosomal-dominant, or X-linked trait. NonMendelian inheritance patterns such as digenic, maternal (mitochondrial) or compound heterozygosity have also been reported. To date, more than 65 genes have been implicated in syndromic and nonsyndromic forms of RP, which account for only about 60% of all RP cases. Due to this high heterogeneity and diversity of inheritance patterns, the molecular diagnosis of syndromic and non-syndromic RP is very challenging, and the heritability of 40% of total RP cases worldwide remains unknown. However new sequencing methodologies, boosted by the human genome project, have contributed to exponential plummeting in sequencing costs, thereby making it feasible to include molecular testing for RP patients in routine clinical practice within the coming years. Here, we summarize the most widely used state-ofthe-art technologies currently applied for the molecular diagnosis of RP, and address their strengths and weaknesses for the molecular diagnosis of such a complex genetic disease.
Introduction
The term Retinitis Pigmentosa (RP) encompasses a broad group of genetically determined retinal diseases caused by a large number of mutations that result in rod photoreceptor cell death followed by gradual death of cone cells, eventually leading to blindness. Thus, typical RP is also described as a rod-cone dystrophy, in which loss of rod function exceeds the reduction in cone sensitivity (Hamel, 2006; Hartong, Berson, & Dryja, 2006) . RP is the most common form of hereditary retinal degeneration with a worldwide prevalence of about 1 in 3500-5000, with a total of more than 1 million affected individuals (Chang et al., 2011; Chizzolini et al., 2011; Collin et al., 2010) . Affected individuals first experience defective dark adaptation (night blindness), followed by reduction of the peripheral visual field (known as tunnel vision) and sometimes, loss of central vision late in the course of the disease. In the progression of RP symptoms, night blindness generally precedes tunnel vision by years or even decades. At the cellular level, the retinal pigment epithelium is altered in most cases, presenting clusters of pigment within the retina of RP patients; hence the name to the disease. The onset, progression and severity of the disease is genetically determined in most cases and also influenced by the mode of inheritance. In extreme cases, patients may present a rapid evolution over two decades, but in contrast, other patients exhibit slow progression, which may never lead to blindness (Hamel, 2006) . Nevertheless, symptoms typically start in the early teenage years and severe visual impairment occurs by ages 40-50 years (Sahni et al., 2011) .
RP can be divided into two groups: non-syndromic RP in which RP is restricted to the eyes, without other systemic manifestations and syndromic RP in which patients present associated non-ocular diseases, the latter representing 20-30% of total cases (Chang et al., 2011; Ferrari et al., 2011) . The most common forms of syndromic RP are: Usher's syndrome, which is characterized by RP and sensoryneural hearing impairment, with or without vestibular dysfunction (Williams, 2008) and the Bardet-Biedl syndrome, which is characterized by RP with obesity, polydactyly, mental retardation, hypogonadism and renal failure in some cases (Beales et al., 1999) . The Bardet-Biedl syndrome is due to mutations in at least 11 genes, with cases of triallelic and digenic inheritance (Hamel, 2006) . On the basis of its inheritance pattern and prevalence, RP can be divided into three main groups: autosomal-dominant (30-40% of cases), autosomal-recessive (50-60%) and X-linked (5-15%). Patients with no other affected relatives are typically autosomal recessive, although a few might represent new dominant mutations, instances of uniparental isodisomy or, for males, X-linked mutations, or even non-Mendelian inheritance patterns, such as digenic inheritance, compound heterozygosity or maternal (mitochondrial) inheritance (Audo, Bujakowska, et al., 2011; den Hollander et al., 2007; Hartong, Berson, & Dryja, 2006) .
Most cases of RP are monogenic. More than 65 associated genes have been identified, 43 of which correspond to non-syndromic RP as of May 2012 (http://www.sph.uth.tmc.edu/retnet/). Most genes for RP cause only a small proportion of cases, with the exception of the rhodopsin (RHO), the USH2A and the RPGR genes which together cause $30% of all cases of RP (Daiger, Bowne, & Sullivan, 2007; Hamel, 2006; Hartong, Berson, & Dryja, 2006; Musarella & Macdonald, 2011; Pomares et al., 2010; Sergouniotis et al., 2011; Waseem et al., 2007) . However, these genes account for only about 60% of all RP patients, while heritability in about 40% of RP patients remains unknown (Daiger, Bowne, & Sullivan, 2007; Ferrari et al., 2011; Sahni et al., 2011) . For an update on genetic and genomic information regarding complex genetic retinal disorders, several databases are available, including: http://www.ensembl.org; http://www.ncbi.nlm.nih.gov; http://www.ncbi.nlm.nih.gov/gene; http://www.ncbi.nlm.nih.gov/homologene; http://www.sph.uth.tmc. edu/retnet/; http://genome.ucsc.edu.
Despite the fact that many technically diverse approaches are being investigated for the treatment of RP, there is currently no standardized and efficient treatment for this disease. The discovery of the molecular basis of the disease has led to the development of several assays in animal models and more recently in human trials, with promising results. More advanced lines of research in RP therapy include: the use of neurotrophic factors (Zhang et al., 2012) ; gene therapy (Allocca et al., 2011; Jacobson et al., 2012; Pang et al., 2011); retinal transplant (MacLaren et al., 2006; West et al., 2012) and electronic prosthesis (Barry & Dagnelie, 2012; Zrenner et al., 2011) .
Several factors have made the molecular characterization of RP a real challenge. These include the high number of genes and variants involved, as well as non-Mendelian inheritance patterns, such as incomplete penetrance, digenic or triallelic inheritance. To further complicate things, two different mutations in the same gene can generate different diseases and the same mutation in different individuals may cause distinctly different symptoms. For instance, although mutations in the rhodopsin gene are usually linked to dominant RP, a few rare rhodopsin mutations can cause recessive RP. Finally, the fraction of disease-causing mutations varies with ethnicity and geography (Daiger, Bowne, & Sullivan, 2007; Ferrari et al., 2011; Hamel, 2006; Stone, 2003) .
Methods to determine DNA sequences were developed in the late 1970s by Frederick Sanger and Walter Gilbert, and have revolutionized the science of molecular genetics. Development of the Chain-Termination method in 1977, and especially publication of the first draft of the human genome in 2001 (Lander et al., 2001; Venter et al., 2001) , have boosted the blossoming of novel technologies that deliver fast, inexpensive and accurate genome information with unprecedented cost-effectiveness, leading to the generation of what is known as Next Generation Sequencing (NGS) technologies. Thanks to these new methods, the technical challenges, time and cost involved in full or partial sequencing of the human genome have exponentially plummeted (Bowne, Humphries, et al., 2011; Ferrari et al., 2011; Lander, 2011) . For instance, the per-base cost of DNA sequencing has dropped by 100,000-fold over the last decade and the current generation of sequencing systems can read up to 250 billion bases in a week compared with 25,000 in 1990 and 5 million in 2000 (Lander, 2011; Service, 2006) . High cost involved in conventional methods of genome sequencing, are responsible of the current lack of large-scale genome sequencing studies aimed at disease gene discovery. However, this may soon change, considering that the cost of sequencing a genome at $1000 per individual is near to becoming a fact (Duggal, Ibay, & Klein, 2011) .
Since the discovery of the rhodopsin gene, the first one directly linked to RP (Dryja et al., 1990) , almost 65 genes have been found to be associated with this disease. Considering recent advances in genomic sequencing, which are changing mutation discovery paradigms, it seems reasonable to assume that the genetic cause of RP will be identified in 90-95% of cases in the near future. Identification and classification of all RP causing mutations will contribute to a better understanding of disease variants and will be central in order to provide improved diagnosis and prognosis for each patient. This is particularly important when children, young adults or affected women planning to have family are involved (Daiger, Bowne, & Sullivan, 2007; Ferrari et al., 2011; Hamel, 2006; Shintani, Shechtman, & Gurwood, 2009) .
In this review, we summarize the most widely used, stateof-the-art technologies currently employed for the molecular diagnosis of RP. We present their main features, advantages and disadvantages and assess their capabilities and limitations to accomplish an accurate molecular diagnosis of such a complex genetic disease. These techniques are presented in two main groups: sequencing technologies and technologies specialized in detecting genetic variants.
Sequencing methods

Chain-Termination or Sanger sequencing
The Chain-Termination sequencing method or Sanger method (Sanger, Nicklen, & Coulson, 1977) has revolutionized molecular biology, providing the backbone technology for DNA sequencing for almost three decades and has led to a number of monumental accomplishments, including the analysis of the whole human genome sequence (Lander, 2011) . This method is considered to be the first-generation technology, with latest technologies being denominated as Next-Generation Sequencing systems (NGSs) (Metzker, 2010) .
The Sanger method is performed in four separate reactions, in each of which are included a DNA polymerase, specific DNA primers flanking the target sequence and the four different types of deoxynucleotides (dNTPs). The key principle of this technique is the use of chain-terminating dideoxynucleotide triphosphates (ddNTPs). One of the four different types of radioactively labeled ddNTPs is added to each reaction. Instead of having an -OH group, like dNTPs, ddNTPs have a hydrogen atom attached to the 3 0 carbon, which causes the termination of the elongation reaction due to their inability to form a phosphodiester bond with the next deoxynucleotide. Thus, DNA chain length in each reaction will depend on how long the chain was when a ddNTP is randomly incorporated. Once the four reactions have been completed, high-resolution electrophoretic separation in a polyacrylamide gel is applied for separating these chains by length with a resolution of one nucleotide (Pettersson, Lundeberg, & Ahmadian, 2009; Shendure & Ji, 2008) . Finally, the gel is dried onto chromatography paper and exposed to X-ray film allowing direct reading of the DNA sequence, where a dark band in a lane indicates a DNA fragment that is the result of chain termination after incorporation of a ddNTP (Fig. 1A) .
In the early 1990s, a methodological improvement of the Sanger method, called Dye Termination sequencing, was introduced and has become the mainstay in automated sequencing. The main improvement of this technique lies in the fact that each ddNTP is labeled with a different fluorescent dye, allowing sequencing in a single reaction, rather than in four as in the Sanger method, with a significant improvement in yield (Fig. 1B) . Current sequencing platforms based on Dye Termination methodology are fully automated and use capillary electrophoresis in a massively parallel way, allowing the analysis of 384 DNA samples in a single run which makes them faster, with implemented simplicity and costeffectiveness and lower error rates, comparing to initial versions (Pettersson, Lundeberg, & Ahmadian, 2009; Shendure & Ji, 2008) .
Sanger sequencing reads, including Dye Termination versions, can reach up to 800-1000 base pairs (bp) with a per-base raw accuracy of near 100%. This accuracy is higher than that achieved with NGS technologies, but has a much higher cost per kb, making this technology particularly inefficient for the generation of genome-size data sets (Table 1) (Fox, Filichkin, & Mockler, 2009; Metzker, 2010; Shendure & Ji, 2008) .
Currently, the main application of this technology is direct sequencing or re-sequencing of amplified selected PCR products (Shendure & Ji, 2008) , allowing analysis of genes and exons at the nucleotide level to elucidate disease-causing mutations. In fact, the Sanger technique is still the only method considered to be the gold standard for single read approaches in clinical sample testing and therefore is the method of choice for concluding molecular diagnosis Janssen et al., 2011; McGee et al., 2010; Rajadhyaksha et al., 2010) .
Reverse dye-terminator (Illumina) sequencing
The Illumina sequencing system (formerly known as Solexa) combines the use of massively parallel clonal amplification with cyclic reversible dye-terminator sequencing (polymerase-based sequencing-by-synthesis). It is able to identify tens of billions of bases per week in a single run, producing high quality sequence data with unprecedented levels of cost-effectiveness and throughput (Pareek, Smoczynski, & Tretyn, 2011) . This has facilitated the sequencing of complex genomes and comprehensive characterization of the widest range of structural variants. It is currently one of the most widely adopted NGS platforms and recent applications of this technology includes the diagnosis of RP (Audo et al., 2012; Bowne, Humphries, et al., 2011; Janssen et al., 2011; Tucker et al., 2011) .
Using focused acoustic waves, the DNA sample is randomly sheared into fragments of 100-300 bp in length, and complementary sequences or adapters are ligated onto both ends of each fragment, increasing fragment size up to several hundred bp (Shendure & Ji, 2008) . Adaptor-ligated DNA fragments are then size separated by electrophoresis and a band between 200 and 300 bp is excised.
Both strands of each size-selected, adapter-ligated DNA fragment are denatured and attached randomly, both forward and reverse, to nearby primers that are already covalently connected to a unique physical location in a solid surface called a flow cell (made up of a dense lawn of adaptor complementary sequences) (Pettersson, Lundeberg, & Ahmadian, 2009; Shendure & Ji, 2008) . Each flow cell is divided into eight separate lanes which allow independent samples to be run simultaneously (Mardis, 2008) . Thereafter, repeated cycles of bridge PCR amplification will generate directly on the surface, very high density colony-like local clusters (>10 million DNA clusters per each lane of the array), containing approximately 1000 copies of each single strand DNA fragment ( Fig. 2) (Metzker, 2010; Pettersson, Lundeberg, & Ahmadian, 2009) .
Sequencing is then carried out using a proprietary cyclic reversible terminator-based method. This method enables detection of single bases as they are incorporated into growing strands with a modified DNA polymerase and a mixture of four nucleotides in each cycle (Shendure & Ji, 2008) . Just like ddNTPs in Sanger sequencing, a fluorescently labeled 3 0 reversible terminator base (RT-base) will stop amplification reactions when it is incorporated. At this time, after laser excitation, the emitted fluorescence (each RT-base emits a different fluorescence signal) from each cluster is captured by a sensitive CCD camera and the first base is identified (Pareek, Smoczynski, & Tretyn, 2011) . Non-incorporated nucleotides are washed away to allow incorporation of the next base. This is possible thanks to a cleavage enzyme that chops all the blocking groups and extra molecules off (fluorophores and nonincorporated bases), and turns the RT-base into a normally functioning nucleotide. Since all four reversible terminator-bound dNTPs (A, C, T, G) are present as single, separate molecules during each sequencing cycle, natural competition reduces the chance of incorporation bias. The end result is true base-by-base sequencing.
Illumina technology, currently the most cost-effective technology among all sequencing platforms, with the highest throughput, is able to generate 10-fold more sequence data for approximately the same cost per run than other NGS technologies. The use of indexes allows the multiplexing of 96 samples per lane, which is a very useful feature when complex genetic diseases such as RP are involved, and reduces significantly the cost per sample (Fox, Filichkin, & Mockler, 2009; Loman et al., 2012) . Its main limitation is its relatively short read length capacity of about 100 bases. This is probably due to dephasing and signal decay produced by incomplete incorporation of nucleotides, incomplete cleavage of fluorescent labels or insufficient removal of reverse terminators. Longer reads are possible but at higher error rates. Thus, average raw error rates are of the order of 0.75% per base for the Illumina GAIIx platform and 0.25% for the Illumina HiSeq 2000 platform, both of which use a paired end sequencing approach (Minoche, Dohm, & Himmelbauer, 2011; Quail et al., 2012) . The dominant error type using Illumina technology is substitution, rather than insertions or deletions, but homopolymers are certainly less of an issue than with other technologies (Elliott et al., 2012; Shendure & Ji, 2008) . Another alternative, such as ABI SOLiD sequencing technology, sequences each nucleotide twice rather than as single bases because it adds bases in pairs through a ligation-based sequencing technique. Thus, while Illumina will read ''TAG'' as ''T'', then ''A'', then ''G'', ABI SOLiD reads it as ''TA'', ''AG'' (Koboldt et al., 2012) . This procedure produces a double sequencing of each base and consequently significantly reduces reading error rates to about 0.15% per base.
Illumina technology can sequence 40,000,000 templates simultaneously with a raw accuracy of >98% and a throughput of 600 Gb per run thanks to the paired-end reads approach, which consists of a simple modification to the standard single-read DNA library preparation. This facilitates reading both forward and reverse template strands of each cluster during one read, allowing alignment of reads with unprecedented precision. The relative success of this platform over other sequencing platforms, such as pyrosequencing (Roche/454 GS FLX) or sequencing by oligonucleotide ligation and detection (ABI SOLiD), is also due to its lower consumable cost per Gb, which is approximately 1% of the cost of Sanger sequencing (Pareek, Smoczynski, & Tretyn, 2011; Pettersson, Lundeberg, & Ahmadian, 2009 ).
Ion Semiconductor (Ion Torrent) sequencing
Ion Torrent Semiconductor sequencing also known as pH-mediated sequencing or silicon sequencing is a rapid (4.5 h per run for 1 Gb output), simple, massively scalable and economical sequencing system. Ion Torrent, rather than relying on optical or imaging technology, measures variations in pH induced by the release of a positively charged hydrogen ion, coupled to nucleotide incorporation, a process coined as ''sequencing by synthesis'' (Glenn, 2011; Rothberg et al., 2011) . Thus, semiconductor sequencing obviates the need for optical methods, electromagnetic intermediates, specialized nucleotides or other technical challenges required in previous sequencing techniques (Glenn, 2011; Pareek, Smoczynski, & Tretyn, 2011; Rothberg et al., 2011; Sanger, Nicklen, & Coulson, 1977) .
The Ion Torrent device uses a high-density array of nano-scale wells to sequence in a massively parallel way. These nano-wells, each holding a different DNA fragment, are on top of a complementary metal-oxide semiconductor chip (CMOS), beneath which is an ion sensitive layer, a pH meter, below which is a proprietary Ion Sensitive Field Effect Transistor Sensor (ISFET) which transmits electrical current (Pareek, Smoczynski, & Tretyn, 2011; Rothberg et al., 2011) . To sequence the template, the DNA to be deciphered is first fragmented. Obtained fragments are then attached to adapters, amplified by emulsion PCR and linked to a nano-well on the chip (Rothberg et al., 2011) . The device is flooded along with each of the four different unmodified bases (dNTPs), one type of base at a time. When a dNTP complementary to the next nucleotide of the fragment is incorporated, pyrophosphate is released and a positively charged hydrogen ion is generated. The charge from the ion changes the pH of the solution, which is detected by the ISFET ion sensor leading to a shift in voltage that is ultimately translated into readout of the DNA being sequenced without scanning, cameras or light mediation. If added dNTP in this cycle are not complementary, no incorporation and no biochemical reaction occurs. Unattached dNTP molecules are washed out and another cycle begins with a different type of base. When the ion sensor is excited, electrical pulses are transmitted by the chip and the software displays the produced data as an ionogram and the sequence can be read from it with no intermediate signal conversion (Fig. 3) .
The presence of a homopolymer stretch on the sequenced DNA causes incorporation of multiple dNTPs, with the corresponding release of hydrogen ions in a single cycle. This causes a proportional increase in pH and therefore in the electronic signal. However signals from those repeats with a 1 base difference are difficult to discriminate. This limitation in accuracy of sequencing highly repetitive regions is shared by other techniques that detect single nucleotide additions, such as pyrosequencing (Elliott et al., 2012; Loman et al., 2012) , and should be taken into consideration, since these regions can be important contributors to heritable diseases (Gonzalez et al., 2007; Pareek, Smoczynski, & Tretyn, 2011) .
The initial scope of this technology was small scale, quick-turnaround jobs like de novo bacterial artificial chromosomes (BACs), plasmids and microbial genome sequencing, microRNA sequencing or targeted re-sequencing, and was limited by the impossibility of making long length reads (Glenn, 2011; Pareek, Smoczynski, & Tretyn, 2011) . The recent launch of the Personal Genome Machine (PGM) and Ion Proton sequencers with enhanced chip density (314, 316 or 318 chips) have improved read length from 100 bp to 200 bp, Mb per run yield (from 10 Mb to 1 Gb) and cost per Mb (about 5-fold) (Glenn, 2011; Robison, 2011) . These two new Ion Torrent sequencers, although sharing semiconductor technology, are designed for different genetic approaches: the PGM sequencer is recommended for small-genome sequencing, sequencing sets of genes, ChIP-Seq, and gene expression approaches, whereas the Ion Proton sequencer is more suited to human genome sequencing projects, including whole genome, exome or transcriptome sequencing (Life Technologies. Ion Proton sequencer and PGM sequencer Data Sheets, 2012).
An advantage of ion semiconductor sequencing over many other approaches is that a simple run can be completed within hours, compared with previous NGS systems which have run times ranging from days up to 2 weeks. The fast performance associated with this technology has allowed the characterization of an Escherichia coli strain in the early stages of a severe pathogenic outbreak by the rapid whole genome sequencing of this microorganism (Mellmann et al., 2011; Robison, 2011) .
Refining of this technology, mainly based on PES methodology, as described in Section 2.2, has allowed improved resolution of insertions and deletions, reducing reading errors by about 5-fold to 0.19% with a reported consensus accuracy of about 1 error per 1000 bases in 100 Mb. However, this accuracy and error data regarding the human genome are exclusively provided by the device manufacturers, with the exception of a recent study for the detection of disease-causing mutations in cystic fibrosis (Elliott et al., 2012) . Using semiconductor sequencing, they reported a false-positive call on the 2184delA in a CFTR locus in 35% of the reads spanning this variant that lies in a homopolymer stretch of seven adenines, which was misinterpreted as a point deletion. For this reason, the current high rate of false positives using semiconductor sequencing makes this technology more suitable for other applications rather than for full gene sequencing, such as hotspot variant detection. Independent data regarding bacterial, viral or non-human mammalian genome sequencing has been reported by several groups (Howden et al., 2011; Mellmann et al., 2011; Miller et al., 2011; Vogel et al., 2012) .
Currently, several companies and universities are offering diagnostic services for RP, using NGS technology. Some examples include: The Casey Eye Institute Molecular Diagnostics Laboratory (Portland, Oregon. USA, https://www.ohsu.edu/xd/health/services/casey-eye/diagnostic-services/cei-diagnostics/tests-we-offer. cfm); the Center of Genomics and Transcriptomic CeGaT (Tuebingen, Germany, http://www.cegat.de/List-of-genes-(by-disease)_l= 1_41.html); the Centrum Medische Genetica (Ghent, Belgium, http://medgen.ugent.be/CMGG/onderzoek.php?topic_id=81); the John and Marcia Carver Nonprofit Genetic Testing Laboratory (Iowa City, IOWA. USA, https://www.carverlab.org/faqs/disease-descriptions/rp); GeneDx (Gaithersburg, Maryland, USA, http://www. genedx.com/test-catalog/disorders/retinitis-pigmentosa-x-linked/); Fundación Jimenez Diaz, http://www.fjd.es/instituto_investiga-cion/es/investigacion/genetica/genetica_genomica.html); and Asper BioTech (http://www.asperbio.com/asper-ophthalmics).
The main features of sequencing technologies reviewed here, as well as other currently available NGS technologies, such as 454 pyrosequencing, ABI SOLiD are summarized in Table 1 . Heliscope and SMRT, also included in the Table 1 , are briefly described in Section 4.
Genetic variant detection methods
DNA microarray technology
Microarray technology, also referred to as DNA chips, is a fast and efficient high-throughput screening and validation technique successfully used in the diagnosis of several pathologies including glioblastoma, colorectal cancer, chronic lymphocytic leukemia, Idiopathic Generalized Epilepsy or autism (Dhawan et al., 2012; Dougherty et al., 2012; Hochstenbach et al., 2011; Jasmine et al., 2012; Leone et al., 2012; Zhang et al., 2011) . For a detailed review of its application in diagnosis see Keren and Le Caignec (2011) and Sato-Otsubo, Sanada, and Ogawa (2012) .
This technology, originally designed to detect genomic copy number variation (CNV) and to perform Single Nucleotide Polymorphism (SNP) genotyping, allows for whole genome analysis of patient samples using a chip-based format. Current improvements in DNA array features have contributed to making them very popular for clinical research purposes. Analysis of thousands to millions of SNPs in parallel can be performed, allowing large-scale genotyping studies with minimal hands-on processing per plate. Applications for DNA arrays currently include clinical genetics and diagnosis, such as: gene expression profiling, alternative splicing detection, loss of heterozygosity testing, uniparental disomy or DNA adenine methyltransferase identification (Bibikova et al., 2006; Gardina et al., 2006; Lin et al., 2004; Lindblad-Toh et al., 2000; Tucker et al., 2012; Vardhanabhuti et al., 2006) .
SNP or polymorphism microarrays
Variation in single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) within individuals play major roles in common human diseases. They may determine the difference between affected and healthy individuals and are being extensively used as genetic markers (Almal & Padh, 2012; Vissers & Stankiewicz, 2012) . SNP or polymorphism microarrays are designed to detect most types of the SNP and CNV variants which have been previously ascertained through several major SNP discovery initiatives, such as NCBI dbSNP, the 1000 Genomes Project, UCSC genome browser's database and the NHLBI Sequencing Project (http://www.ncbi.nlm.nih.gov/projects/SNP/; http:// www.1000genomes.org/; http://genome.ucsc.edu/ and http://www. nhlbi.nih.gov/resources/exome.htm; Hoffmann et al., 2012; Kim & Misra, 2007; Rocha et al., 2006; Schaaf, Wiszniewska, & Beaudet, 2011; Smith, 2008; Sung et al., 2012) .
Microarrays are miniature devices made of silicon glass ($1 cm 2 ) composed of millions of micrometer-scale beads or wells, each holding hundreds of thousands of identical copies of short single-stranded DNA oligonucleotides -the probe -immobilized at a different and strategic position on the array. Probes exploit the natural chemical attraction between DNA strands to hybridize or to selectively anneal only to those DNA molecules with a perfect match. Therefore such arrays can be used to identify the presence of a particular allele in the context of a single individual's entire genome.
Attending to the purpose of the study, DNA arrays can be divided in two main groups: those arrays used for the molecular diagnosis of specific genetic disorders, which typically require identification of hundreds to a few thousands of SNPs in parallel (Krjutskov et al., 2008; LaFramboise, 2009; Nevelin et al., 2012 ; Piñeiro-Gallego et al., 2011) and another group of arrays capable of performing parallel analysis of millions of SNPs, commonly used for genome-wide association study (GWAS), which are efficient to locate genes or loci that may harbor disease alleles (Duggal, Ibay, & Klein, 2011; Hoffmann et al., 2012; Hunter et al., 2007; Levine et al., 2012; Rodenburg et al., 2012) .
Among the molecular diagnosis-oriented arrays, Arrayed Primer Extension or APEX microarray technology, combines hybridization and four-color single-base primer extension reactions. This technology can genotype hundreds to thousands of genetic variations in parallel, including single base substitutions, deletions and insertions (Krjutskov et al., 2008; Pereiro et al., 2011; Shumaker, Metspalu, & Caskey, 1996) .
The APEX reaction consists of a three-step reaction mechanism: (1) amplification of targeted DNA which harbors mutations or SNPs of interest; (2) hybridization between targeted DNA and primers attached to the beads (acting like probes) designed to hybridize immediately adjacent to the loci of interest, stopping one base before the interrogated marker; and (3) single base enzymatic extension using a thermostable DNA polymerase together with four different terminator nucleotides each tagged with a different fluorophore. The newly incorporated nucleotide terminates the extension reaction and represents the base of interest. Then, four lasers (one at a time) are used to excite the different dyes and the light emitted is uses to interrogate the nature of the nucleotide in the position of interest . It requires about 2.5-6 lg of genomic DNA and 2 days to perform the assay.
APEX microarrays for the diagnosis of non-syndromic and syndromic RP are commercially available. Non-syndromic RP variants which can be diagnosed include adRP (covering 414 variants in 16 genes), arRP (594 variants in 19 genes) and X-linked RP (184 mutations in 2 genes). Syndromic RP, such as Bardet-Biedl syndrome (over 300 variants in 13 genes), or Usher syndrome (612 mutations in 9 genes) can also be identified (Audo, Bujakowska, et al., 2011; Audo et al., 2012; Avila-Fernandez et al., 2010; Dev Borman et al., 2012; Jaijo et al., 2010; Kimberling et al., 2010; Mackay et al., 2011; Vozzi et al., 2011; Yzer et al., 2006) . For an updated list of DNA arrays available see (http:// www.asperbio.com/asper-ophthalmics).
There are currently two main manufacturers of GWAS-oriented arrays. Both of these work on the same biochemical principal of base-paring, but with some differences: Illumina arrays determine SNP genotypes by the single-base extension technique, whereas Affymetrix arrays use single or multiple base mismatch hybridization technology (LaFramboise, 2009; Perkel, 2008; Schaaf, Wiszniewska, & Beaudet, 2011) .
In Affymetrix SNP arrays, probes of about 25 nucleotides long, representing all possible alleles at a polymorphic site (typically a pair), are attached to the 8 lm array beads. Once isolated, amplified, fragmented and fluorescently labeled, the DNA target sequence is applied to the chip, which will hybridize only to those probes which are perfectly complementary. The array is scanned and the intensity of fluorescent signals is measured to quantify the relative amount of sample bound to each bead. The position of fluorescent signals within the array will identify which alleles are present in that particular genome sample. Affymetrix arrays are capable of determining in a single assay up to 1.8 million common and rare validated genetic variants, including insertion/ deletions, which typically require 500 ng of genomic DNA and 3-4 days, for an average SNP reported call rate of >99% and an average sample repeatability of >99.8% (Affymetrix Genome-Wide Human SNP Array 6.0. data sheet). This technology has been chosen for genotyping in projects related to retinal disorders (Bowne, Humphries, et al., 2011; Gonzalez-del Pozo et al., 2011; Ostergaard et al., 2011; Roesch, Stadler, & Cepko, 2012) .
On the other hand, the Ilumina SNP array uses the single-base extension technique and a dual color channel approach to identify and score up to 4.3 million markers per single DNA sample. Unlike the Affymetrix assay, which utilizes one probe type per all possible alleles in a locus, the Illumina chip only uses a single probe -of about 50 bases -per locus. In this case, the probe is designed to hybridize immediately adjacent to the locus of interest, stopping one base before the interrogated marker, thereby not containing the SNP itself. By using this approach, there is no need to design a different probe for each SNP in each locus, thereby increasing the capacity of SNP genotyping (Schaaf, Wiszniewska, & Beaudet, 2011) .
In Illumina SNP arrays, DNA target hybridizes to a locus-specific bead. Then, SNP locus-specific primers are extended in the presence of labeled dideoxynucleotides (biotin-labeled ddCTP and ddGTP, and dinitrophenyl group-labeled ddATP and ddUTP). These dideoxynucleotides are efficiently incorporated by polymerases and detected in a dual-color assay. Bead fluorescence is analyzed using Illumina software for automated genotype calling, based on color and signal intensity (Steemers et al., 2006) . With respect to sample requirements, 750 ng of DNA is sufficient to process over 500,000 SNP loci in 3 days, with an average SNP reported call rate and reproducibility of about 100% (Illumina HumanOmni5-Quad BeadChip data Sheet). Recent studies were based on Illumina BeadChips to perform genome-wide homozygosity screening for arRP and X-linked RP families (Kannabiran et al., 2012; Siemiatkowska et al., 2011) .
The main drawback of microarray-based genotyping, is that it is only valid for known genetic variants, excluding newly discovered SNPs. Both Illumina and Affymetrix are now producing arrays with two components: one determined and another customizable, in which researchers can incorporate a limited number of last minute discovered SNPs. This allows researchers to tailor the SNP chip to their needs, although at a significantly higher chip cost.
Taqman OpenArrays (Applied Biosystems) offer a fully customizable array platform, which allows researchers to design custom arrays to detect any new SNP. This technology uses the 5 0 exonuclease activity of the Taq polymerase, together with two Taqman probes to discriminate between the two alleles of an SNP. Taqman probes consist of two oligonucleotides, each complementary to one of the two alleles of the SNP, with a fluorophore covalently attached to the 5 0 -end and a quencher at the 3 0 -end. Quencher molecules suppress the fluorescence emitted by the fluorophore when excited by the cycler's light, as long as the fluorophore and the quencher are close enough. During the annealing-extension step, the probe hybridizes to the amplicon and polymerase breaks the union between the quencher and the DNA, resulting in an increase of fluorescence due to physical separation of the quencher from the fluorophore. The emitted fluorescence is directly proportional to the amount of DNA and indicates the type of alleles that are present in the sample. The Taqman OpenArray platform contains 3072 microscopic through-holes grouped in 48 subarrays of 64 through-holes each, enabling the parallel genotyping of up to 256 different SNPs per array. Running time for this assay is about 8 h from purified DNA to genotyping results and 125 ng of DNA is required per sample (Hopp et al., 2010; Pomeroy et al., 2009; Roberts et al., 2009) .
More recently, a fully customizable platform has become available; the qBiomarker PCR array (SABioscience; Qiagen) allows the complete design of an array with the SNPs chosen by the researcher (patent pending).
High Resolution Melting (HRM) analysis
High Resolution Melting (HRM) analysis is a fast and cost-effective post-PCR analysis method that provides a rapid identification of genetic variation, based on biophysical measurement of the amplified DNA (Aguirre-Lamban et al., 2010; Carrillo et al., 2012; Dufresne et al., 2006; Sergouniotis et al., 2011; Smith, Lu, & Alvarado Bremer, 2010; Vossen et al., 2009) . Transition of the double-stranded DNA molecule to its two single strands -DNA denaturation or melting -allows the study of DNA structure and composition by measuring the change of fluorescence intensity per unit of time. HRM gives valuable information for mutation screening, genotyping, methylation, microsatellite analysis and other research applications (Arthofer, Steiner, & Schlick-Steiner, 2011; Mader, Lukas, & Novak, 2008) .
HRM is faster (1.5-3 h), simpler and less expensive than other DNA variation analysis techniques, due to the lack of addition, processing or separation steps involved (Erali & Wittwer, 2010) . Reaction and analysis take place in the same instrument (closed-tube method) minimizing manipulation errors (Reed, Kent, & Wittwer, 2007) . These facts contribute to making HRM analysis more sensitive and specific than other techniques, such as denaturing high performance liquid chromatography (dHPLC), single-strand conformation polymorphism (SSCP) and restriction fragment length polymorphism (RFLP) Joly et al., 2011) . Recent availability of advanced double-stranded DNA (dsDNA)-binding dyes, along with next-generation real-time PCR instrumentation and analysis software have increased its sensitivity and accuracy and have improved the clinical potential of this technology.
HRM analysis starts with targeted PCR amplification in the presence of a dsDNA-binding dye. Mutations can be detected at any location in the amplicon, including those located right after the primer sequences. As the PCR product gradually dissociates into single strands, dye is released with a strong loss of fluorescence emission related to the process ($1000-fold decrease). Emitted fluorescence is measured with specialized instrumentation which generates a precise characteristic curve from a large number of fluorescent data points per change in temperature. By measuring the melting temperature (Tm: when 50% of the DNA is doublestranded), amplicons that differ by only a single base compared with reference wild type (WT) samples can be resolved (Dufresne et al., 2006; Vossen et al., 2009 ).
An interesting feature of HRM analysis is its power to detect all categories of variations, including substitutions, inversions, insertions and deletions, ranging from single to 63 bp mutations, provided that they are small enough to be amplified by PCR, with forward and reverse primers bracketing the variation (Bastien et al., 2008; De Leeneer et al., 2008; Dufresne et al., 2006; Kennerson et al., 2007; Reed, Kent, & Wittwer, 2007; van der Stoep et al., 2009 ). Thus, multi-exon deletions may remain undetected by this technique (De Leeneer et al., 2008) .
The sensitivity of heterozygote detection is remarkable, with several studies reporting detection of all heterozygous mutations examined (Audrezet et al., 2008; Kennerson et al., 2007; Lonie et al., 2006; Takano et al., 2008) . Homozygous variants differ in Tm from the WT samples whereas heterozygous variants produce a remarkable modification in curve shape, rather than in Tm. The latter are better resolved by using melting curve advanced plots, such as ''Difference Plot'', where small differences in melt curve data are amplified (Liew et al., 2004) .
Changes in Tm are base-specific. Class I (C/T; G/A) and II (C/A; G/T) produce a greater change in Tm, with an average of >0.5°C, compared with class III (C/G), with an average of 0.2-0.5°C or class IV (A/T), with an average of <0.2°C. Thus, mutations involving class III and IV are associated with a decreased sensitivity of homozygote detection (Liew et al., 2004; Sergouniotis et al., 2011) . One approach that can be used to increase the power of resolution of single point mutations is to add WT DNA to control and unknown samples (at a 1:6 ratio) to create artificial heterozygotes, with all genotypes distinguished by quantitative heteroduplex analysis (Seipp, Herrmann, & Wittwer, 2010; Wittwer, 2009) . Factors other than sequence that can generate small differences in Tm include: genomic quality, primers design, amplicon length and PCR reagent choice, including dye selection and ionic strength (Liew et al., 2004) . Amplicon lengths ranging between 100 and 300 bp, including primers, are generally recommended for sequence variant detection.
Mutation discovery in human diseases has been the largest area of HRM application, with investigations into autosomal dominant, recessive and X-linked disorders (Cherbal et al., 2012; Kennerson et al., 2007; Krypuy et al., 2007) . To date, hundreds of mutations in more than 60 genes have been analyzed with this technology, including genes associated with RP, such as C2ORF71, USH2A or ABCA4 Sergouniotis et al., 2011; Xu et al., 2011) . We have recently found HRM analysis to be an appropriate approach as a massive genetic screening method when combined with direct sequencing, being particularly suited for relatively small (<4 kb) RP genes with medium/high prevalence, such as USH3A, PRPF31 or ROM1 (Anasagasti et al., 2012) (Fig. 4) .
Multiplex Ligation Probe Amplification (MLPA)
The technique known as MLPA is an accurate, time-efficient and kit-based laboratory tool able to detect unusual copy number changes in genomic sequences, with high sensitivity and specificity (Fernandez et al., 2005) . This method is specialized in detecting large genomic rearrangements, i.e., deletions and duplications, including entire gene exons that frequently escape conventional and novel laboratory detection methods, including NGS (Schouten et al., 2002) . Therefore, the MLPA technique has been frequently used in molecular diagnosis of patients with genetic disorders caused by deletions or duplications in specific genes, such as Duchenne Muscular Dystrophy (DMD), Charcot-Marie-Tooth disease or mental retardation (Dastur et al., 2011; Madrigal et al., 2007; Marzese et al., 2008) . Deletions and duplications represent about 5% of all disease-causing mutations, and recent data show that this might be of relevance in some cases of RP (Daiger, Bowne, & Sullivan, 2007; Roux et al., 2011; Sullivan et al., 2006) . Another application of this genomic DNA technology includes SNP detection, aneuploidy determination and DNA methylation analysis, as well as RNA based applications such as RT-MLPA and mRNA profiling (Diego-Alvarez et al., 2007; Slater et al., 2003) .
MLPA is a multiplex PCR-based screening method designed to determine in a single reaction tube the copy number of up to 50 DNA or RNA sequences, up to 96 samples in parallel in 24 h (Chung et al., 2012; Stuppia et al., 2012; Vorstman et al., 2006) . Unlike standard multiplex PCR, where amplification using unique primer pairs for each fragment is required, MLPA reaction is performed with only a single primer pair for all its probes, avoiding dimerization or false priming issues. The principle of MLPA is based on the identification of target sequences by hybridization of two oligonucleotides (fluorescently labeled MLPA probes) that can be joined to each other by a ligation reaction, only when hybridized to the target sequence. Each oligonucleotide has a PCR primer attached to facilitate posterior identification (Vorstman et al., 2006) . Once joined, MLPA sequences will then be exponentially amplified during PCR, providing a unique mixture of fragments ranging between 65 and 500 bp in length, which can be identified and quantified by capillary electrophoresis and analyzed using an automatic sequencer. This allows estimating the amount of product obtained by emission of a signal peak that can be visualized as an electropherogram (Fernandez et al., 2005) . Comparison of the peak probe pattern emitted by the target sample with that emitted by a control sample enables the detection of abnormal probe signals that indicate variations in copy number, indicating either deletion or duplication of genomic regions of interest (Vorstman et al., 2006) . A calculated ratio from this comparison that falls outside the range of 0.85-1.35 would indicate deletions or duplications of the sample sequence involved.
Zygosity can also be determined by ratio comparison, since both homozygous deletions and duplications will produce greater genetic change and therefore greater change in ratios with respect to the control sample than heterozygous deletions and duplications. Interpretation of data can be done using MLPA specific software (Vorstman et al., 2006 ). An important application of this method is the determination of the relative ploidy of target samples. If an extra gene copy is present in the target sample, a 1.5-fold increase in emitted signal is predicted to occur, depending on the zygosity of insertion. In contrast, if a gene copy in the target sample is missed, the emitted signal is expected to be 0.5 times the intensity of the control probes in heterozygosis, with a complete lack of signal in homozygosis.
Currently, MLPA kits containing all the necessary reagents to perform diagnostic screening for many genetic disorders such as Duchenne Muscular Dystrophy (DMD) (Dastur et al., 2011; Laing et al., 2011) , Becker Muscular Dystrophy (BMD) Lehmann-Horn et al., 2011) , Marfan Syndrome (Faivre et al., 2010; Furtado et al., 2011) , von Willebrand disease (Cabrera et al., 2011) or Aniridia (Lim et al., 2012) are commercially available. As far as Retinitis Pigmentosa is concerned, there are several MLPA Kits marketed for genes associated with this disease, such as PRPF-31, PCDH15, RPGR, ABCA4, LCA or USH2A (Fig. 5) Rose et al., 2011; Roux et al., 2011) . Inconveniences of MLPA technology include the existence of only one supplier (MRC Holland), and the possibility of having an SNP under the probe.
For a comparative summary of the main advantages and limitations of the different technologies described in the present review, see Table 2 .
Future directions
Nowadays, we are experiencing a quantum shift in sequencing capacity, with benchtop devices being capable of unveiling genome sequences at unprecedented time and cost. It seems plausible thus to predict that molecular diagnosis for RP patients will become a routine procedure in clinical practice over the coming years. Nevertheless, due to the complexity of this eye disorder at many different levels, a number of important issues still need to be resolved. For instance, at least 40% of RP-related genes remain to be identified, disease-causing mutations must be detected and classified, mutation testing must become inexpensive, reliable and widely available and, clinicians must become familiar with the molecular procedures used in order to communicate the relevant information to patients. In this respect, one of the limitations of NGS platforms is the interpretation of the huge amount of data generated. A multidisciplinary network of clinicians, molecular biologists and bioinformaticians will have to be established, if we want to extract relevant biological information from the terabytes of data that many laboratories are generating already.
New NGS platforms continue to appear on the market and will surely contribute to further changing the human genome sequencing paradigm. These include Helioscope, SMRT or Nanopore technologies. The principal advantages associated with these new technologies, in addition to greater cost-effectiveness include: (1) sequencing based on single molecule DNA, eliminating the need for PCR amplification, with a significant simplification of the process and reduction of data generated; (2) read lengths are significantly higher than with Dye Termination sequencing, reaching up to 10,000 bp and (3) significant increase in data produced per time invested. Note however that this information is based on data provided by the following manufacturers, with no independent validation: http://www.helicosbio.com/Products/HelicosregGeneticAnalysisSystem/tabid/140/Default.asx-http://www.pacificbiosciences.com/-http://www.nanoporetech.com/).
